RAPT Therapeutics (RAPT)

• Market cap: $749M
• 1 day: 1.41%
• 5 days: 0.4%
• 1 month: 16.79%
• 3 months: 178.89%
• 6 months: 306.48%
• Year to date: 130.98%
• 1 year: 77.59%
• 5 years: -87.09%
• 10 years: -71.04%
• Sector: Healthcare
• Industry: Biotechnology

About: RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Employees: 61